Table 2.
Propensity-weighted, adjusted quality of care differences between pilot and comparison practices among continuously enrolled patients.
| Pilot | Comparison | Difference (95% CI) | P value | |
|---|---|---|---|---|
| Diabetes: HbA1c testing* | %** | |||
| Pre-intervention | 93.5 | 93.5 | NA*** | NA |
| Intervention year 1 | 94.4 | 88.2 | 6.2 (1.9, 10.5) | 0.005 |
| Intervention year 2 | 95.0 | 90.7 | 4.2 (−0.1, 9.2) | 0.092 |
| Intervention year 3 | 92.1 | 83.9 | 8.3 (2.3, 14.2) | 0.007 |
| Diabetes: LDL-C testing | ||||
| Pre-intervention | 90.5 | 90.5 | NA | NA |
| Intervention year 1 | 90.8 | 86.5 | 4.3 (−2.1, 10.6) | 0.188 |
| Intervention year 2 | 91.8 | 86.3 | 5.5 (−0.9, 11.9) | 0.093 |
| Intervention year 3 | 88.1 | 79.6 | 8.5 (0.3, 16.7) | 0.043 |
| Diabetes: Nephropathy monitoring | ||||
| Pre-intervention | 78.0 | 78.0 | NA | NA |
| Intervention year 1 | 87.7 | 66.2 | 21.5 (14.4, 29.6) | <0.001 |
| Intervention year 2 | 87.2 | 71.4 | 15.8 (7.0, 24.6) | 0.001 |
| Intervention year 3 | 85.6 | 70.2 | 15.5 (5.4, 25.5) | 0.003 |
| Diabetes: Eye exams | ||||
| Pre-intervention | 55.2 | 55.2 | NA | NA |
| Intervention year 1 | 58.0 | 42.5 | 15.5 (7.4, 23.6) | <0.001 |
| Intervention year 2 | 54.5 | 44.9 | 9.7 (−0.5, 19.8) | 0.061 |
| Intervention year 3 | 51.2 | 39.2 | 12.0 (2.8, 21.1) | 0.011 |
| Breast cancer screening | ||||
| Pre-intervention | 81.4 | 81.4 | NA | NA |
| Intervention year 1 | 83.0 | 78.9 | 4.1 (2.0, 6.2) | <0.001 |
| Intervention year 2 | 82.7 | 75.9 | 6.8 (4.5, 9.0) | <0.001 |
| Intervention year 3 | 80.5 | 74.9 | 5.6 (2.9, 8.3) | <0.001 |
| Colorectal cancer screening | ||||
| Pre-intervention | 37.1 | 37.1 | NA | NA |
| Intervention year 1 | 43.4 | 42.9 | 0.5 (−1.3, 2.3) | 0.57 |
| Intervention year 2 | 47.4 | 47.3 | 0.1 (−2.3, 2.5) | 0.95 |
| Intervention year 3 | 50.0 | 51.1 | −1.1 (−4.0, 1.7) | 0.44 |
Abbreviations: NA, Not Applicable; CI, confidence interval.
Measure denominators are 674 pilot and 258 comparison patients for diabetes measures, 2316 pilot and 1714 comparison patients for breast cancer screening, and 4072 pilot and 2410 comparison patients for colorectal cancer screening.
Percentage point estimates are propensity-weighted recycled predictions from linear probability models adjusting for practice baseline score, health plan contributing each observation, and whether each patient was in an HMO product at the time of the observation. Differences, confidence intervals, and p-values correspond to marginal differences from the linear probability models.
Due to the inclusion of fixed effects for practices, regression models do not estimate pre-intervention differences between pilot and comparison.